| Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy S Soverini, M Mancini, L Bavaro, M Cavo, G Martinelli Molecular cancer 17, 1-15, 2018 | 219 | 2018 |
| Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update L Bavaro, M Martelli, M Cavo, S Soverini International journal of molecular sciences 20 (24), 6141, 2019 | 94 | 2019 |
| Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study S Soverini, L Bavaro, C De Benedittis, M Martelli, A Iurlo, N Orofino, ... Blood, The Journal of the American Society of Hematology 135 (8), 534-541, 2020 | 92 | 2020 |
| SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis G Martinelli, M Mancini, C De Benedittis, M Rondoni, C Papayannidis, ... Leukemia 32 (1), 139-148, 2018 | 34 | 2018 |
| In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of … S Soverini, C De Benedittis, F Castagnetti, G Gugliotta, M Mancini, ... BMC cancer 16, 1-6, 2016 | 33 | 2016 |
| Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors M Mancini, S De Santis, C Monaldi, L Bavaro, M Martelli, F Castagnetti, ... Journal of Experimental & Clinical Cancer Research 38, 1-11, 2019 | 17 | 2019 |
| BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia … S Soverini, M Martelli, L Bavaro, C De Benedittis, S Sica, F Sorà, A Iurlo, ... Leukemia 35 (7), 2102-2107, 2021 | 16 | 2021 |
| FOXM1 transcription factor: a new component of chronic myeloid leukemia stem cell proliferation advantage M Mancini, F Castagnetti, S Soverini, E Leo, C De Benedittis, G Gugliotta, ... Journal of Cellular Biochemistry 118 (11), 3968-3975, 2017 | 13 | 2017 |
| Next‐generation sequencing improves BCR‐ABL1 mutation detection in Philadelphia chromosome‐positive acute lymphoblastic leukaemia S Soverini, M Martelli, L Bavaro, C De Benedittis, C Papayannidis, ... British Journal of Haematology 193 (2), 271-279, 2021 | 7 | 2021 |
| Detection of actionable BCR-ABL1 kinase domain (KD) mutations in chronic myeloid leukemia (CML) patients with failure and warning response to tyrosine kinase inhibitors (TKIs … S Soverini, M Martelli, L Bavaro, C De Benedittis, A Iurlo, S Galimberti, ... Blood 134, 661, 2019 | 6 | 2019 |
| Compound BCR-ABL1 kinase domain mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a prospective series of Philadelphia chromosome … S Soverini, L Bavaro, M Martelli, C De Benedittis, A Iurlo, N Orofino, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 6 | 2018 |
| Digital droplet PCR is a fast and effective tool for detecting T315I mutation in chronic myeloid leukemia S Galimberti, F Guerrini, S Grassi, M Bocchia, L Bavaro, E Ciabatti, ... EHA Libr 294653, 2, 2020 | 4 | 2020 |
| Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid … P Vannuffel, L Bavaro, F Nollet, A Aynaci, M Martelli, H Devos, C De Rop, ... Blood 134, 4660, 2019 | 3 | 2019 |
| SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia M Mancini, S De Santis, C Monaldi, L Bavaro, M Martelli, F Castagnetti, ... Blood 130, 43, 2017 | 3 | 2017 |
| Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis M Mancini, S De Santis, C Monaldi, L Bavaro, M Martelli, G Gugliotta, ... Hematological oncology 38 (2), 201-203, 2020 | 2 | 2020 |
| BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now? S Soverini, M Martelli, L Bavaro The Lancet Haematology 6 (5), e236-e237, 2019 | 2 | 2019 |
| Next generation sequencing-based bcr-abl1 kinase domain mutation screening in de novo and tyrosine kinase inhibitor-resistant philadelphia chromosome-positive acute … S Soverini, L Bavaro, M Martelli, C De Benedittis, C Papayannidis, ... Blood 132, 4078, 2018 | 1 | 2018 |
| MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment M Mancini, C Monaldi, S De Santis, C Papayannidis, M Rondoni, ... Blood 132, 1779, 2018 | 1 | 2018 |
| Polo-like kinase-1 and aurora kinase a as novel therapeutic targets in neoplastic mast cells M Mancini, C Monaldi, S De Santis, C Papayannidis, M Rondoni, ... Blood 130, 5290, 2017 | 1 | 2017 |
| What's Next in CML-a prospective study evaluating sanger sequencing and next generation sequencing (NGS) for BCR-ABL1 kinase domain (KD) mutation screening S Soverini, L Bavaro, C De Benedittis, M Martelli, S Stella, P Vigneri, ... Blood 130 (Supplement 1), 248-248, 2017 | 1 | 2017 |
